Financial Performance - Net profit attributable to shareholders rose by 52.83% to CNY 32,098,671.81 year-on-year[10] - Operating income grew by 25.41% to CNY 183,580,539.38 compared to the same period last year[10] - The gross profit margin for product sales improved to 81.93%, up 1.40 percentage points from 80.53% in the previous year[13] - Total revenue for Q1 2023 reached ¥183,580,539.38, a 25.4% increase from ¥146,385,175.70 in Q1 2022[96] - Operating profit for Q1 2023 was ¥38,039,673.76, up from ¥25,293,248.56 in Q1 2022, reflecting a growth of 50.4%[97] - Net profit for Q1 2023 was ¥32,098,671.81, compared to ¥21,002,890.48 in Q1 2022, representing a 52.7% increase[97] - Basic earnings per share for Q1 2023 were ¥0.50, up from ¥0.32 in Q1 2022, indicating a 56.3% rise[98] Asset and Liability Management - Total assets increased by 5.53% to CNY 1,054,021,928.02 compared to the end of last year[10] - The company's asset-liability ratio (consolidated) was 19.20%, up from 18.12% at the end of last year[10] - Total liabilities as of March 31, 2023, were ¥202,371,923.95, compared to ¥180,994,603.95 at the end of 2022, showing an increase of approximately 11.7%[90] - The company's equity attributable to shareholders rose to ¥851,650,004.07 from ¥817,808,946.31, reflecting an increase of about 4.1%[90] Cash Flow and Investment - Cash flow from operating activities decreased by 59.46% to CNY 16,891,051.11 compared to the same period last year[10] - The total cash inflow from investment activities in Q1 2023 was ¥303,166,673.58, significantly higher than ¥31,466,927.14 in Q1 2022[104] - The net cash flow from investment activities for Q1 2023 was -¥47,419,011.15, compared to a positive cash flow of ¥1,237,726.73 in Q1 2022[104] - The company incurred a credit impairment loss of -¥2,161,825.60 in Q1 2023, compared to -¥330,072.43 in the same period last year[101] Shareholder and Stock Management - The total number of unrestricted shares at the end of the period was 44,895,944, representing 68.82% of total shares[20] - The total share capital at the end of the period was 65,240,500 shares, with 3,938 shareholders[20] - The largest shareholder, Li Yong'an, holds 6,761,216 shares, accounting for 10.36% of total shares[21] - The company has a significant number of shareholders (11 individuals) holding a combined 54.11% of shares, acting in concert[22] - The core employee shareholding decreased from 2,128,086 to 1,156,007 shares, a drop of 972,079 shares[20] Compliance and Regulatory Commitments - The company has no ongoing litigation or arbitration matters during the reporting period[26] - There were no significant changes in accounting policies or errors during the reporting period[19] - The company is committed to compensating for any administrative penalties due to non-compliance with regulatory requirements, ensuring equal economic compensation[44] - The company has ongoing commitments to fulfill its obligations regarding the issuance of shares and related disclosures, ensuring transparency and compliance[42] - The company will not conduct public refinancing until new commitments are fulfilled or remedial measures are implemented[74] Research and Development - The company emphasizes strengthening R&D investment and market expansion to enhance competitive and sustainable profitability capabilities[52] - Research and development expenses for Q1 2023 were ¥16,377,476.77, up from ¥14,753,104.23 in Q1 2022, reflecting an increase of 11.0%[97] Future Plans and Strategies - The company plans to continue expanding its product offerings and market presence, with new products expected to launch soon[11] - The company plans to improve production processes and operational efficiency, targeting increased inventory turnover and enhanced asset utilization[53] - The company will expedite the investment progress of fundraising projects to achieve expected benefits as soon as possible, aiming to increase shareholder returns in subsequent years[53]
德源药业(832735) - 2023 Q1 - 季度财报